Analyzing Auxilium Pharmaceuticals (AUXL) & Its Peers
Auxilium Pharmaceuticals (NASDAQ: AUXL) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Auxilium Pharmaceuticals to similar businesses based on the strength of its risk, analyst recommendations, earnings, dividends, valuation, institutional ownership and profitability.
Institutional and Insider Ownership
43.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Auxilium Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals’ competitors have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
This table compares Auxilium Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxilium Pharmaceuticals Competitors||-13,602.79%||-100.87%||-25.29%|
Valuation & Earnings
This table compares Auxilium Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Auxilium Pharmaceuticals Competitors||$564.12 million||$96.15 million||12,061.17|
Auxilium Pharmaceuticals’ competitors have higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations and price targets for Auxilium Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxilium Pharmaceuticals Competitors||132||798||1740||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential downside of 98.12%. Given Auxilium Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Auxilium Pharmaceuticals has less favorable growth aspects than its competitors.
Auxilium Pharmaceuticals competitors beat Auxilium Pharmaceuticals on 5 of the 8 factors compared.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.